Last reviewed · How we verify
NCT04451473
Lung Surgery With Enhanced Recovery VS. Lung Surgery Without Enhanced Recovery
NA trial testing Enhanced Recovery After Surgery (ERAS ) in Lung Cancer in 350 participants. Currently enrolling.
30 June 2023
Quick facts
| Lead sponsor | The Second Hospital of Shandong University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 350 |
| Start date | 8 October 2019 |
| Primary completion | 30 June 2023 |
| Estimated completion | 30 June 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Enhanced Recovery After Surgery (ERAS )
- Traditional perioperative management without Enhanced Recovery After Surgery (ERAS )
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
- Surgery — all drugs for Surgery →
- ERAS — all drugs for ERAS →
Sponsor
The Second Hospital of Shandong University
Who can join
Adults 18 to 85, any sex, with Lung Cancer or Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Objective: The adoption of Enhanced Recovery Surgery programs in lung resection is relatively recent with limited outcome data. This study aimed to determine the impact of an Enhanced Recovery Surgery pathway on short- term and long- term results in patients undergoing lung resection for primary lung cancer. Methods: A Randomized Controlled Trial was designed to collect the perioperative data on consecutive patients undergoing lung resection for primary lung cancer. Patients will be randomizely assigned to the ERAS- Group and Control- Group. Short-term and long- term effect will be compared between the two groups.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Video- assisted thoracoscopic lung resection with or without enhanced recovery after surgery: a single institution, prospective randomized controlled study.
Ding Y, Zhou L, Shan L, Zhang W, et al · · 2024 · cited 5× · PMID 39582544 · DOI 10.3389/fonc.2024.1474438
Verify or expand the search:
- PubMed search for NCT04451473
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other The Second Hospital of Shandong University trials
Trials by the same sponsor.
- NCT07430579 — Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma · NA · recruiting
- NCT06337968 — CPB for Arthroscopic Hip Surgery · NA · not yet recruiting
- NCT06604091 — Cohort Profile：The Shandong Adenomyosis Cohort of Population Undergoing Reproductive Technology (SAart) · active not recruiting
- NCT06574958 — Clinical Study of CD38\CS1 Chimeric Antigen Receptor T Cells in the Treatment of Refractory/Recurrent Multiple Myeloma · EARLY_PHASE1 · active not recruiting
- NCT06572956 — Clinical Study on the Safety and Efficacy of CAR-T/CAR-NK Cells in the Treatment of Recurrent Refractory or Unresectable · EARLY_PHASE1 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04451473 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Second Hospital of Shandong University
- Last refreshed: 16 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04451473.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing